Lichen Planopilaris Is One of the Leading Causes of Permanent Hair Loss. Most People With It Have Never Had Its Root Causes Investigated.

Lichen Planopilaris is a chronic inflammatory condition that targets the hair follicle causing scarring alopecia, a form of hair loss in which the follicle is permanently destroyed and replaced with fibrous scar tissue. Unlike non-scarring hair loss conditions where the follicle remains intact and regrowth is possible, LPP destroys the follicle itself making regrowth in affected areas impossible once scarring is established. This is what makes early identification and intervention so critical, the window for preserving follicles and halting progression is finite. LPP is an immune mediated condition in which the immune system attacks the hair follicle stem cell region, the bulge stripping it of the immune privilege that normally protects it from attack. What drives that loss of immune privilege is identifiable and addressable.

‍

LPP presents in several distinct clinical patterns. 

• Classic LPP affects the central and vertex scalp with patchy hair loss surrounded by perifollicular scaling and erythema. 
• Frontal Fibrosing Alopecia also known as FFA is a variant of LPP that predominantly affects the frontal hairline and eyebrows and has become significantly more prevalent in recent decades particularly in postmenopausal women. 
• Graham-Little-Piccardi-Lasseur Syndrome is a rare variant combining scalp scarring alopecia with non-scarring body hair loss and follicular papules. 

Each variant shares the same fundamental immune mechanism but differs in distribution and associated features and all require the same root cause investigation.

FFA was considered extremely rare before the 1990s. Its prevalence has increased dramatically over the past three decades in a pattern that strongly suggests environmental and hormonal drivers beyond genetics alone. Proposed contributors include widespread use of leave-on facial sunscreens and cosmetic products containing UV filters that have been found in affected scalp tissue, hormonal shifts particularly in postmenopausal women, rising rates of autoimmune susceptibility driven by gut dysbiosis and intestinal permeability, and vitamin D deficiency. The dramatic increase in prevalence within a short timeframe makes a purely genetic explanation insufficient.

LPP is frequently misdiagnosed as other forms of alopecia such as androgenetic alopecia, alopecia areata, or seborrheic dermatitis particularly in early stages before obvious scarring develops. Dermoscopy and scalp biopsy are required for definitive diagnosis but are not always performed when hair loss is attributed to more common causes. The result is that many people with LPP spend years being treated for the wrong condition while irreversible follicular damage continues. Early biopsy in any case of progressive hair loss with scalp symptoms is essential.

LPP is managed as a localised inflammatory skin condition requiring immune suppression at the scalp level. What it actually reflects is a systemic immune dysregulation operating in the context of compromised gut integrity, hormonal imbalance, nutrient deficiencies impairing immune regulation, and environmental triggers, the same upstream terrain driving other autoimmune conditions. Topical and injected corticosteroids, hydroxychloroquine, and other systemic agents reduce the inflammatory attack on the follicle. They do not restore the immune terrain that lost tolerance to the follicle in the first place. Address that terrain and disease activity very often reduces further slowing or halting progression and in some cases achieving sustained remission.